PARTI Overview Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. By harnessing the RNAi pathway, we have pioneered a new class of innovative medicines, known as RNAi therapeutics. RNAi therapeutics a...
guided guidance are non - GAAP financial measures that exclud e from the corresponding GAAP measures stock - based compensation expense estimated at $345M - $375M in both the Prior FY 2025 Guidance and
Q3 FY2025
guidance
ALNY
guided Guidance • Total TTR Net Product Revenues (PN & CM) (AMVUTTRA, ONPATTRO) $2,175 to $2,275 million
Q3 FY2025
guidance
ALNY
guided Guidance Non - GAAP Combined R&D and SG&A Expenses 3 $2,100 to $2,200 million
Q3 FY2025
guidance
ALNY
guided FY 2025 Guidance and the Updated FY 2025 Guidance Item Total Net Product Revenues 1 $2,650 to $2,800 million
Q3 FY2025
topic_mention
ALNY
discussed Supply Chain
Q4 FY2024
topic_mention
ALNY
discussed Regulation
Q4 FY2024
topic_mention
ALNY
discussed Sovereign & Government
Q4 FY2024
topic_mention
ALNY
discussed Automotive
Q4 FY2024
topic_mention
ALNY
discussed Healthcare & Bio
Q4 FY2024
topic_mention
ALNY
discussed Platform & Ecosystem
Q4 FY2024
guidance
ALNY
guided Guidance
12 Disrupting an Expanding Growth Market 1 Information based on Alnylam modeling data Significant Unmet Patient Need ~80% ATTR - CM patients undiagnosed globally 1 RAPID KNOCKDOWN